MedTrace Logo

Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer

NCT05168254 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-12-23

No results posted yet for this study

Summary

The early symptoms of pancreatic cancer are not obvious, and the early diagnosis rate is low. For most patients with pancreatic cancer,palliative chemotherapy is the only choice .At present, The guidance of NCCN guidelines on the selection of chemotherapy regimens for patients with advanced pancreatic cancer is only based on the physical condition(the ECOG score), which is one of the important reasons for the poor efficacy of chemotherapy in patients with advanced pancreatic cancer.Therefore, it is urgent to group pancreatic cancer patients according to tumor molecular typing and heterogeneity of response to chemotherapy drugs accurately,so as to guide the personalized treatment of patients.

Conditions

  • Pancreatic Ductal Adenocarcinoma, PDAC

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Duowu Zou · Ruijin Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-07-01
Completion
2022-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05168254 on ClinicalTrials.gov